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Abstract 
 The growing prevalence and pervasiveness of type 2 diabetes (DMII) constitutes a global 
health crisis. The current guideline-based treatment strategies for DMII feature a stepwise 
titration and addition of oral and/or injectable agents to assist in improving glycemic parameters 
while minimizing the development of common complications. However, this strategy leaves 
relatively unopposed the pathophysiological processes that underlie DMII – beta-cell dysfunction 
and insulin resistance. There is a gathering research effort dedicated to the development and 
refinement of a novel disease-modifying treatment that alters the natural history of DMII through 
rapid resolution of hyperglycemia, reversal of insulin resistance, and restoration of beta-cell 
secretory function. This treatment is called short-term intensive insulin (STII) therapy and 
involves subjecting patients to 2-3 weeks of insulin administration to bring about a rapid return 
to normoglycemia. A collection of 16 pertinent studies that address and investigate this novel 
treatment modality was assembled during a comprehensive literature search utilizing several 
academic literature search databases. After scrutiny of methodology and synthesis of findings, it 
was concluded that STII therapy is a superior alternative to current treatment approaches with 
respect to the following outcomes: improvement of beta-cell function, reversal of insulin 
resistance, attainment of glycemic control, achievement and maintenance of drug-free glycemic 
remission, and safety. In addition, investigators have identified several patient factors that 
increase the likelihood of achieving remission. Although more research is certainly warranted, 
this novel therapy is positioned to be embraced and employed by providers and specialty 
organizations that publish DMII practice guidelines. 
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Early Short-term Intensive Insulin Therapy: A Disease-modifying 
Treatment Approach for Type 2 Diabetes 
The following is an all-too-familiar scenario that plays out on a daily basis in primary 
care offices everywhere: A moderately-overweight middle-aged patient presents to the clinic for 
a routine visit to monitor type 2 diabetes management. She was diagnosed two years ago and has 
made little, if any, progress toward achievement and maintenance of normoglycemia despite 
lifestyle modification and escalation of oral antidiabetic drug therapy. She has known 
neurovascular complications and comorbid hypertension and hyperlipidemia. As medication 
doses are increased and the addition of other agents is considered, the provider longs for the 
existence of a disease-modifying therapy that could alter the natural history of DMII by reversing 
the two pathophysiologic processes at the heart of DMII – beta-cell dysfunction and insulin 
resistance. Fortunately, there is currently underway a research movement with a goal to make 
this wish a reality for patients like the one mentioned above.  
Type 2 diabetes (DMII) represents a global health crisis in demand of urgent intervention. 
Arising out of an interplay of both non-modifiable and modifiable risk factors, DMII is a chronic 
health problem that is exploding in worldwide prevalence and exacting an ever-increasing toll on 
health, quality of life, and economic and healthcare resources. The International Diabetes 
Federation reports that the worldwide prevalence of DMII in 2013 was around 340 million (or 
8.5% of those individuals over 18 years of age) with that number expected to grow to 530 
million by 2035 (Saisho, 2014). DMII is a leading cause of blindness, kidney failure, heart 
attack, stroke, and lower extremity amputation worldwide, with diabetic complications directly 
implicated in anywhere between 2.2 million and 5.1 million deaths per year (Saisho, 2014). 
Further, it is estimated that treatment of DMII and its complications account for 10.8% of total 
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worldwide healthcare expenditures (Saisho, 2014). It is imperative that this be addressed before 
it becomes a global health catastrophe.  
The current treatment approach for DMII typically involves starting with a trial of 
lifestyle modifications with the hope that euglycemia can be restored in a non-pharmacological 
manner. If not successful, this is usually followed by addition of an oral antidiabetic drug (most 
often metformin) with subsequent escalation of the dose until satisfactory glycemic control is 
achieved. If this is not achieved, the stepwise addition of other oral medications from other 
classes and/or injectable agents (either GLP-1 agonists or insulin) takes place until Hgb A1c 
reaches the treatment goal. This strategy, although successful in reestablishing short-term 
glycemic control in many cases, simply corrects hyperglycemia while the underlying 
pathophysiological processes of DMII continue in the background. This permits the disease to 
advance insidiously, which is reflected by the need for progressive intensification of therapy and 
the eventual necessity of exogenous insulin administration. 
 DMII develops after an individual, due to the interplay of modifiable and non-modifiable 
risk factors, experiences a sustained level of hyperglycemia that reinforces and amplifies itself by 
directly inhibiting pancreatic beta-cell function (both through the phenomenon of glucotoxicity 
and by increasing secretory workload) and by contributing to the development of tissue-level 
insulin resistance. As insulin sensitivity deteriorates, hyperglycemia becomes more pervasive, 
beta-cell function and mass decline further, hyperglycemia intensifies, DMII complications 
develop, and treatment begins to demand continual escalation until exogenous insulin is required 
due to total secretory failure of beta-cells.  
Therapy failure, much like that illustrated in the presented case, is too often experienced 
using current guideline-based management approaches. In fact, it is believed that fewer than 50% 
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of those with a high Hgb A1c are receiving treatment that would be considered optimized 
(Weng, 2017). Further, when metformin is started as a sole agent at DMII diagnosis, a 17% per 
year treatment failure rate is noted (Weng, 2017). Many believe that this is the case because the 
underlying pathophysiological features of DMII – beta cell dysfunction and insulin resistance – 
continue to worsen despite the use of conventional treatment strategies (Weng, 2017)   
It has been posited that some level of beta-cell dysfunction is present up to 12 years 
before the diagnosis of DMII, and insulin sensitivity and secretion are already detectably 
abnormal 3-6 years before diagnosis (Hanefeld, 2014). Further, obese individuals with DMII 
have been found on autopsy to have 65% less beta-cell mass than those without DMII, and beta-
cell function may have already decreased by 80% by the time impaired glucose tolerance is first 
noted (Saisho, 2014). It is not surprising, then, that many researchers assert that treatment is 
started too late in the process and that, when treatment is started, it should center on the reversal 
of beta-cell damage / death and the restoration of beta-cell secretory function. There is a belief, 
based on scientifically-generated evidence, that the use of insulin for a short period (2-3 weeks) 
near the time of DMII diagnosis can help restore beta-cell function and insulin sensitivity in such 
a dramatic way that there is, after the short-term intensive insulin (STII) period, a real possibility 
of experiencing a drug-free remission period during which normoglycemia can be maintained 
with lifestyle modification alone (Weng et al., 2015).  
Even though its addition is usually inevitable (usually at an average of 9 years after DMII 
diagnosis), insulin is typically one of the final introductions to currently-used therapy regimens. 
Newer research evidence tends to suggest that insulin is added far too late, with the average Hgb 
A1c at insulin initiation being 9.5% (Home et al., 2014). At that point, about 90% of patients 
have experienced at least one DMII-related complication, and fewer than 10% of beta-cells are 
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even functional (Home et al., 2014). Because of these findings, there has been a growing interest 
in utilizing a short burst of intensive insulin therapy at the time of diagnosis in order to achieve 
these effects and alter the natural history of DMII. This paper will attempt to critically evaluate 
and formulate a synthesis of the research literature that addresses the novel DMII treatment 
modality that is known as short-term intensive insulin (STII) therapy. Specifically, the role of 
STII will be investigated as it relates to the following parameters: beta-cell function, insulin 
resistance, glycemic control, rates of drug-free remission, incidence of hypoglycemia, and 
predictors of glycemic remission versus relapse. 
Case Report 
 A 45-year-old female presented to her primary care provider’s office at the prompting of 
her diabetes educator due to patient reports of high morning home blood glucose readings. She 
was diagnosed with type 2 diabetes (DMII) two years earlier and has struggled with her glycemic 
control having implemented lifestyle modifications (including weight loss attempt, healthier diet, 
increased aerobic activity, and diabetes education) in addition to taking 1000 mg of metformin 
daily. Her initial A1c upon diagnosis was 9.6%, and her fasting plasma glucose was 267 mg/dL. 
She elected to solely try lifestyle modifications at that time, but after failing to lower her 
glycemic parameters by 3- and 6-month follow-up appointments, she agreed to begin taking 
1000 mg daily of metformin. During the subsequent 1.5 years, she has continued monthly 
appointments with the diabetes educator and has tried unsuccessfully to make lasting weight, 
diet, and activity modifications. She has been reluctant to escalate her pharmacologic therapy 
despite never having lowered her A1c to below 8.2% during the past 2 years. She sees an eye 
provider for diabetic eye exams every year and reports no issues. Her kidney function has 
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remained acceptable thus far. However, she has been experiencing symptoms of progressive 
peripheral neuropathy in her lower extremities since before her diagnosis.  
 In addition to metformin, she also takes the following daily medications: aspirin 81 mg, 
lisinopril 20 mg, atorvastatin 20 mg, and a daily multivitamin. Her blood pressure has been well-
controlled up to this point with the ACE inhibitor, but her lipid profile has never reached 
satisfactory status for someone with DMII (LDL >130). She has no history of other significant 
medical problems. Her mother, maternal grandmother, and paternal grandfather all suffer from 
DMII, and her maternal grandmother has had a myocardial infarction. She is married, has two 
school-aged children, and works outside of the home as a cook. 
 During the visit, her physical exam was unremarkable with the exception of marked 
reduction of sensation bilaterally in her feet during a 10-point monofilament exam. Her review of 
symptoms revealed no vision changes, nausea, vomiting, polyuria, chest pain, shortness of 
breath, or changes in level of consciousness. Her labs during the visit were as follows: A1c 8.5% 
(previous 8.3%), FPG 178 (previous 145), TSH 6.4, Free T4 0.8, total cholesterol 187, HDL 43, 
LDL 133 (previous 128), triglycerides 180 (previous 195), serum creatinine 0.69 (previous 0.72), 
urine albumin-to-creatinine ratio 16 mg albumin/gram creatinine (previous 17).  Her weight is 
stable (BMI 28), and the only abnormal vital sign during her visit was blood pressure, which was 
148/98 mmHg. Qualitatively, her history, exam, vital signs, and lab studies demonstrate 
continued poorly-controlled DMII with peripheral neuropathy (though without renal or retinal 
complications) in the setting of less-than-ideal serum lipid levels (specifically LDL and 
triglycerides) and elevated blood pressure.  
 At the conclusion of this visit, after all the available history, exam, and laboratory data 
had been reviewed and synthesized, the following treatment plan was formulated and 
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implemented by the patient and provider: 1) Greater effort would be assigned to weight loss, 
eating a healthier diet, and increasing activity level to feature 150 minutes a week of semi-
vigorous exercise, 2) Double the daily dose of metformin to 2000 mg, 3) Double the daily dose 
of atorvastatin to 40 mg, 4) Double the daily lisinopril dose to 40 mg, and 5) Return in 3 months 
to evaluate progress toward achieving control of glycemic profile, lipid levels, and blood 
pressure with the anticipation of escalating DMII therapy. 
Literature Review 
 A comprehensive literature search was conducted utilizing CINAHL, PubMed, and the 
Cochrane Library. A search of Google Scholar was also included with the goal of returning 
guidelines and other grey literature that may not be unearthed in a formal search of the 
bibliographic databases. CINAHL was searched first with the following limits applied to the 
search strategy: “English language,” “peer-reviewed,” and “publishing dates 2010-2018.” With 
these filters in place, a search was performed utilizing the CINAHL Headings Diabetes, Type 2, 
and Insulin in combination with the keywords intensive OR short-term. Sixty-six citations were 
returned, and after title and abstract review, it was determined that 6 of these articles directly 
addressed the clinical phenomenon at hand. The remaining studies were not pertinent and were 
discarded.  
The Cochrane Library was searched next with results limited to articles published 
between 2010 and 2018. In the first search, the MeSH Term Insulin was combined with the 
MeSH Term Diabetes, Type 2. This yielded 2,767 citations, so the keyword intensive was added 
to the search strategy, and this yielded a more-manageable queue of 78 citations. After title and 
abstract review, 8 pertinent citations remained, which included one systematic review and 7 
trials. Various combinations of the MeSH Term Diabetes Mellitus, Type 2 with the keywords 
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intensive, insulin, and diagnosis were searched, yielding several citations, the most pertinent of 
which being duplicates of those yielded in the initial Cochrane search.  
  Finally, PubMed was searched with the following limits applied to the search strategies: 
“English,” “human subjects,” “free full text,” and “published in the last 5 years.” The first search 
involved combining the MeSH Terms Insulin and Diabetes, Type 2 with the terms intensive, new 
and diagnosis, which returned 22 citations, 2 of which were kept after title and abstract review 
and after accounting for duplicates from the Cochrane and CINAHL searches. The second search 
combined the keywords intensive, insulin, and Type 2 Diabetes, which produced 136 results, 5 of 
which were kept after title and abstract review and after accounting for duplicates from all 
previous searches. The third search combined the keywords intensive, insulin, therapy, Type 2 
Diabetes, and diagnosis, which returned 103 citations, 2 of which were kept after title and 
abstract review and after accounting for duplicates from all previous searches. This brought the 
total number of relevant citations from PubMed to 9. 
In total, twenty-three articles deemed germane to the clinical topic in question were 
obtained during the comprehensive literature search of CINAHL, PubMed, and the Cochrane 
Library. Additionally, a search of Google Scholar unearthed two sets of professional clinical 
practice guidelines that had not yet been yielded by the aforementioned database searches. This 
brought the total number of relevant manuscripts for this literature review to 25. Sixteen of these 
were analyzed and evaluated on their merit as evidence to support the recommendation to 
implement STII therapy early in DMII. 
Summary of Findings 
 To evaluate the quality of the evidence yielded in the literature search and grade the 
strength of the practice recommendation based on it, the Strength of Recommendation 
EARLY SHORT-TERM INTENSIVE INSULIN THERAPY 
 
11 
Taxonomy (SORT), which was developed by the American Academy of Family Physicians, was 
utilized (Ebell et al., 2004). Table 1, which can be found at the end of this paper, presents a list 
of the 16 included articles, each with a practice recommendation, respective SORT evidence 
level assignment, and strength of recommendation grade. Below is a synthesis and discussion of 
the evidence as it pertains to the effects of STII therapy on beta-cell function, insulin resistance, 
and glycemic control (disease-oriented outcomes), as well as the patient-oriented outcomes of 
safety, drug-free remission incidence, and predictive factors of remission. 
 Eleven manuscripts mentioned STII favorably in terms of preserving and improving beta-
cell function in DMII (H. Chen, Wu, & Kuo, 2014; Chon et al., 2017; Hanefeld, 2014; Harrison, 
Adams-Huet, Li, Raskin, & Lingvay, 2014; Kramer, Zinman, & Retnakaran, 2013; Kramer, 
Choi, Zinman, & Retnakaran, 2013; J. Liu et al., 2013; Presswala & Shubrook, 2011; Retnakaran 
& Zinman, 2012; Weng et al., 2015; Zhang, Chen, Yang, Wang, & Li, 2016). Notably, Kramer et 
al. (2013) found in their meta-analysis that STII contributed to a 13% improvement in beta-cell 
function, with one-third of the study subjects having experienced > 25% improvement after STII 
therapy. Zhang et al. (2016) determined that beta-cell secretory function actually increased 8-fold 
after a brief period of STII therapy in subjects experiencing glycemic remission. Further, 
Harrison et al. (2014) noted that the beta-cell preservation effects attributed to STII therapy are 
still detectable 6 years after therapy. These studies are highly suggestive that STII therapy exerts 
a direct positive effect on the secretory capacity of beta-cells. 
Seven studies demonstrated improvement in insulin resistance after STII therapy (H. 
Chen et al., 2014; Q. Cheng et al., 2015; Kramer, Choi et al., 2013; Kramer, Zinman et al., 2013; 
J. Liu et al., 2013; Weng et al., 2015; Zhang et al., 2016). Of note, in their meta-analysis, 
Kramer, Zinman, et al. (2013) reported a 43% reduction of insulin resistance after STII, and 
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Zhang et al. (2016) found that insulin sensitivity was increased by 100% in those subjects who 
achieved drug-free remission after STII therapy. Q. Cheng et al. (2015) also reported a 
significant improvement in the Matsuda Index (a surrogate for insulin resistance) after a short 
period of STII therapy. These data make a strong case for the beneficial effects of STII therapy 
on insulin sensitivity by direct reversal of mechanisms responsible for insulin resistance. 
Both short- and long-term glycemic control were found to be positively affected by STII 
therapy in 10 studies (H. Chen et al., 2014; Q. Cheng et al., 2015; Chon et al., 2017; Hanefeld, 
2014; Harrison et al., 2014; Kramer, Zinman et al., 2013; J. Liu et al., 2013; Presswala & 
Shubrook, 2011; Retnakaran & Zinman, 2012; Weng et al., 2015). In their RCT featuring a 6-
year follow-up, Harrison et al. (2014) reported a dramatic decrease in subjects’ A1c from 10.8% 
to 5.9% after 3 months of STII therapy, and after 6 years of conventional oral antidiabetic (OAD) 
therapy post-STII, 69% of patients still exhibited a Hgb A1c < 7%. An 8-study review conducted 
by Hanefeld (2014) also revealed long-lived significant reductions in A1c and FPG in those 
subjects who underwent STII therapy. Retnakaran and Zinman (2012) also reported that 
significantly more individuals who took part in STII therapy early in DMII achieved and 
maintained euglycemia (demonstrated by A1c and FPG) at 1 year post-intervention than those 
who were managed via standard OAD therapy. Finally, in a case report, Presswala and Shubrook 
(2011) described a patient who initially exhibited a Hgb A1c that was too high to be measured 
who was subjected to a basal-bolus STII therapy for 15 weeks, after which his Hgb A1c was 
measured at 6.4%. Without any further pharmacologic intervention, his Hgb A1c was 6.0% at 1 
year and 6.7% after 27 months post-STII (Presswala & Shubrook, 2011). The above studies 
illustrate the ability of STII therapy to rapidly achieve (and often maintain) glycemic control. 
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The induction of drug-free glycemic remission, which is arguably the most exciting 
potential benefit associated with STII therapy, was reported in 11 of the papers returned during 
the literature search (H. Chen et al., 2014; Chon et al., 2017; Hanefeld, 2014; Kramer, Zinman et 
al., 2013; Kramer, Zinman, Choi, & Retnakaran, 2016; J. Liu et al., 2013; L. Liu et al., 2015; 
Presswala & Shubrook, 2011; Retnakaran & Zinman, 2012; Weng et al., 2015; Zhang et al., 
2016). Hanefeld (2014) found that 66.2% of individuals enjoyed drug-free remission (A1c < 7%) 
at 3 months post-STII therapy, and 42% of these were still in remission at 24 months. Kramer, 
Zinman et al. (2013) reported a 56% remission rate at 48 weeks post-STII, while Zhang et al. 
(2016) reported that 50% of their study subjects remained in remission at 1 year post-STII 
therapy. Similarly, Retnakaran and Zinman (2012) found that 44.9% of those who underwent 
brief STII therapy were in remission at 1 year versus only 26.7% of those who underwent 
intensive therapy with OAD during the same time period. Chon et al. (2017) also compared STII 
therapy with OAD in terms of remission and reported that significantly more subjects in the STII 
group achieved and maintained remission, with the STII group enjoying 52.2% less risk of 
relapse at 2 years post-STII therapy (Chon et al., 2017). 
One potential barrier to widespread use of STII therapy is fear of exogenous insulin-
related hypoglycemia. Eight of the manuscripts returned during the literature search featured 
study of this, with all of the investigators reporting that STII therapy is a safe modality if 
properly administered. (H. Chen et al., 2014; Q. Cheng et al., 2015; Chon et al., 2017; Harrison 
et al., 2014; Kramer, Choi et al., 2013; L. Liu et al., 2015; Presswala & Shubrook, 2011; Weng et 
al., 2015). H. Chen et al. (2014) reported zero episodes of hypoglycemia in their study, while 
Chon et al. (2017), L. Liu et al. (2015), Presswala and Shubrook (2011), and Weng et al. (2015) 
reported a very low incidence of hypoglycemic events (and none of a serious nature) during the 
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course of STII therapy. This array of evidence seems to support the safety of using STII therapy 
in an outpatient setting, as long as patients are prepared and deemed capable of managing their 
regimen. 
Much of the research that has addressed STII therapy has found, unfortunately, that not 
all type 2 diabetic individuals respond favorably to the same degree after STII therapy. For 
instance, even though initial improvements in glycemic control, beta-cell function, and insulin 
sensitivity are generally seen in all patients after STII therapy, these effects vary in magnitude 
and duration. Furthermore, because it is felt that the amelioration of these pathophysiological 
components of DMII is what permits the development of drug-free remission, it is no surprise 
that not all subjects experience remission, and in those who do, their remission periods vary in 
length. It would be helpful, therefore, to identify any patient factors that may make remission 
more or less likely to occur and persist.  
The literature search identified 8 manuscripts that reported discovery of patient factors 
predictive of remission (A. Chen et al., 2012; L. Cheng et al., 2016; Kramer, Choi et al., 2013; 
Kramer, Zinman et al., 2013; Kramer et al., 2016; J. Liu et al., 2013; L. Liu et al., 2015; Zhang et 
al., 2016).  Kramer, Zinman et al. (2013) and Kramer et al. (2016) found that lower baseline Hgb 
A1c, higher baseline BMI, and lower baseline FPG were independently predictive of achieving 
and maintaining glycemic remission after STII. L. Cheng et al. (2016) reported that a shorter 
time interval between STII initiation and achievement of glycemic goal is also prognostic of 
achievement of drug-free remission. Zhang et al. (2016) directly measured acute glucagon 
response (AGR) during STII and found that a greater magnitude of reduction was noted in those 
who ultimately achieved remission. A. Chen et al. (2012) demonstrated that positive attitude, 
higher educational attainment, and patient compliance and self-care ability are factors found 
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more often in those who experience remission. Kramer et al. (2016) concluded that the patient 
factor most influential in terms of predictive value of remission is duration of DMII, with less 
than 2 years since onset seemingly being the ideal timeframe. 
Limitations of Evidence and Barriers to Implementation 
 The evidence presented in the 16 included studies is unequivocally complimentary of the 
beneficial effects of STII therapy in early DMII. However, despite the therapeutic promise of this 
modality, there are some criticisms of the evidence that warrant discussion. First, several of the 
early studies that investigated the benefits of STII on the natural history of DMII were small, 
single arm intervention studies (no control group) that were conducted at a few centers in China. 
Methodological issues like lack of randomization, no control groups, and small study size may 
justifiably call into question the validity of some of the resulting data. Another criticism of the 
evidence touted by early studies is that some of them required hospitalization of study subjects 
for the duration of STII therapy, which calls into question the practicality of this form of 
treatment. Additionally invoked as a criticism of earlier evidence is lack of consistency regarding 
the choice of insulin delivery mode utilized for STII therapy (i.e. some studies used continuous 
subcutaneous infusion and others used basal-bolus injection protocols).  
Although these criticisms and limitations are all valid, their merit has been fading 
recently as more studies have been conducted that look at multi-ethnic populations in the 
outpatient setting with results that seem to mimic the earlier studies. Further, a handful of the 
newer multi-center studies have featured larger numbers of enrolled subjects in addition to the 
investigators’ implementation of more rigorous methodological standards. The array of returned 
manuscripts used in this literature review reflect this progressive evolution of study quality, as 
shown by the distribution of SORT evidence levels assigned to the studies. That being said, there 
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continues to be a need for more and larger outpatient-based, multi-ethnic RCTs that use multiple 
daily injections (instead of continuous subcutaneous infusion) as the STII delivery mode of 
choice when investigating the benefits of this therapy. 
Looking past the ever-improving issues related to evidence limitations, there are other 
barriers to widespread adoption of STII therapy as a disease-modifying therapy in early DMII. 
These barriers can be broken down into two categories: patient factors and provider factors. 
Patient factors representing barriers include cost (insulin, needles, home meters, follow-up 
provider visits), fear and/or unpalatability of needles/self-injection, need for high degree of 
compliance and reliability, the health belief or perception that insulin signifies the presence of 
advanced disease, potential for insulin-related weight gain, and the necessity to be prepared and 
equipped to recognize and treat hypoglycemic episodes (Home et al., 2014; Weng, 2017). 
Considerable effort by provider and patient will likely be necessary to overcome these barriers. 
 From a provider barrier standpoint, the term “clinical inertia” has been applied in this 
instance by Home et al. (2014) to describe the phenomenon where providers are reluctant to 
adopt a progressive treatment modality due to comfort and ease in employing the current 
established treatment. For example, due to the nature of STII therapy and its dissimilarity with 
current treatment guidelines, there may be a perception by primary care providers that it is 
aggressive, foreign, and not within their capacity to manage. As pervasive as this inertia is, it is 
intensified when providers do not experience pressure from guideline-publishing authorities to 
espouse the new treatment. Based on the DMII practice guidelines published by the American 
Diabetes Association and the American Association of Clinical Endocrinologists / American 
College of Endocrinology (neither of which mentions STII therapy as a treatment option), the 
hesitation of U.S. providers to adopt STII therapy in their primary care practices is not 
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unexpected (Garber et al., 2017; Rhinehart et al., 2017). Slightly more liberal is the joint position 
statement published by the ADA and the European Association for the Study of Diabetes that 
prescribes a patient-centered approach to DMII management permitting prompt reversal of 
hyperglycemia using insulin when a patient presents initially with ketosis, catabolic features, or 
very deranged glycemic profiles (Inzucchi et al., 2015). The most progressive guideline found in 
the literature search was published by the Israeli National Diabetes Council. The authors 
described how short-term insulin use has been shown to abolish glucotoxicity, and, ultimately, 
preserve beta-cell function (Mosenzon, Pollack, & Raz, 2016). They suggested that STII be 
considered for any individual who presents with an A1c > 9%, with or without symptoms of 
DMII. Given what is known about the disease-modifying benefits of STII, its absence of mention 
within American-based DMII treatment guidelines is a mystery. As new evidence of high quality 
emerges in favor of implementation of STII therapy, appropriate changes to practice and 
management guidelines should ideally come to reflect this with the appropriate adoption by 
primary care providers to follow. 
Conclusion 
 Based upon the review of available and current literature, there is a compelling indication 
to implement early and aggressive STII therapy in DMII. STII therapy leads to rapid resolution 
of hyperglycemia, which mitigates the negative effects of gluco- and lipotoxicity on beta-cell 
function, directly reverses insulin resistance, reduces beta-cell secretory stress (i.e. provides beta-
cell “rest”), and diminishes the acute glucagon response. The overall result of the action of STII 
therapy on beta-cell function and insulin sensitivity is an evidence-substantiated safe promotion 
of normoglycemia that has the potential to lead to short- or even long-term drug-free glycemic 
remission. Patient factors that make this remission more likely to occur and persist are higher 
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BMI, lower baseline fasting plasma glucose and A1c, faster time to glycemic goal after STII 
initiation, positive attitude, greater self-care ability and compliance, higher educational level 
attained, and, most importantly, a shorter duration of DMII. As DMII continues to devastate the 
lives of more patients with each passing year, there is a need to identify and implement new 
disease-modifying treatment modalities that are successful in stalling and even reversing the 
progression of the key pathophysiological features of this disease. STII therapy seems to hold 
much promise in serving as such a treatment. 
Learning Points 
• When implemented early in DMII, STII therapy, which usually consists of 2-3 weeks of daily 
insulin administration, has been shown to safely alter the natural history of type 2 diabetes by 
quickly restoring normoglycemia, reversing insulin resistance, improving beta-cell function, 
and blunting the acute glucagon response. 
• The positive effects of short-term intensive insulin therapy on insulin resistance, beta-cell 
function, and the acute glucagon response have been shown to safely facilitate the 
achievement of drug-free glycemic remission in up to 65% of individuals, with this remission 
persisting in about 50% of subjects at one year and 42% of subjects at 2 years. 
• Some patient factors that have been found to predict achievement and maintenance of drug-
free remission are as follows: higher baseline BMI, lower baseline Hgb A1c and FPG, shorter 
duration of DMII, positive attitude, greater compliance and self-care ability, and higher 
educational level attained. 
• Providers and guideline-publishing groups have been slow to adopt STII therapy as a 
treatment option. More studies are needed to solidify its place and clarify issues such as ideal 
length of STII therapy and how to dose multiple daily injection regimens. 
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    Note. STII - Short-term intensive insulin; COAD – combined oral anti-diabetic drug therapy; OAD – oral anti-diabetic drug therapy; TTG = Time to (glycemic) goal 
Paper / Study Recommendation Based on Results Level of Evidence (based on AAFP SORT) Strength of 
Recommendation  
Retnakaran & Zinman, 
2012 
STII therapy should be considered at DMII diagnosis in 
certain patients as a means to improve glycemic profiles, 
beta-cell function, and insulin sensitivity in the hope that 
drug-free remission can be induced. 
Level 1 Evidence – Systematic Review of several trials 
that addressed remission, beta-cell function, glycemic 
parameters, and predictors of remission after STII 
therapy 
A 
Kramer, Zinman, & 
Retnakaran, 2013 
STII therapy should be initiated at diagnosis to improve 
underlying pathophysiology of DMII and alter its natural 
history.  Remission can be predicted based on baseline 
patient characteristics. 
Level 1 Evidence – Systematic Review and Meta-
analysis of 7 studies that addressed beta-cell function, 
insulin resistance, remission, and predictors of 
remission after STII 
A 
Harrison et al., 2014 Initiate insulin-based short-term intensive therapy early in 
DMII, as it can generate improvements in beta-cell function 
and glycemic control that last for at least 6 years. 
Level 1 Evidence – RCT with 6 year follow up looking 
at beta-cell function and glycemic control in insulin-
based vs. triple oral therapy after STII therapy 
A 
Chen, Wu, & Kuo, 
2014 
Institute STII therapy early in the course of DMII.  After 
the initial STII period, the continued use of insulin glargine 
(instead of standard COAD) extends glycemic benefit. 
Level I Evidence – RCT of high quality that compared 
COAD versus continuing insulin after 10-14 days STII 
therapy on long term glycemic control 
A 
Hanefeld, 2014 Utilize STII therapy early in DMII.  It can improve beta-
cell function, insulin sensitivity, and glycemic control, as 
well as potentially induce drug-free remission.  Reduction 
in major CV events are likely a benefit of early intensive 
glycemic control. 
Level I Evidence – Systematic Review and Meta-
analysis of 5 studies addressing beta-cell recovery, 7 
studies addressing remission, and 8 studies addressing 
glycemic control after STII 
A 
Chen et al., 2012 Positive attitude, higher educational level attained, self-care 
adherence and ability, lower insulin resistance at baseline, 
and greater improvement of acute insulin response are 
independent predictors of remission after STII 
Level 2 Evidence -Case control that addressed baseline 
characteristics of those who achieved remission after 
STII 
B 
Liu et al., 2013 Fasting plasma glucose at end of STII is an independent 
predictor of relapse.  (Higher = greater risk of relapse) 
Level 2 Evidence - Case Control that addressed fasting 
plasma glucose as risk factor for relapse after STII B 
Kramer, Choi, Zinman, 
& Retnakaran, 2013 
Reduction of insulin resistance was an independent 
predictor of greater improvement of beta-cell function.  Can 
be used to predict who will experience remission vs. 
relapse. 
Level 2 Evidence - Case control that addressed insulin 
resistance change as predictor of remission vs. relapse 
after STII 
B 
Table 1.  
Level of Evidence and Strength of Recommendation for each of the 16 articles reviewed.  Determinations were formulated utilizing the Strength of 
Recommendation Taxonomy (SORT), which was developed and published by the American Academy of Family Physicians (Ebell et al., 2004). 
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Note. STII - Short-term intensive insulin; COAD – combined oral anti-diabetic drug therapy; OAD – oral anti-diabetic drug therapy; TTG = Time to (glycemic) goal 
Paper / Study Recommendation Based on Results Level of Evidence (based on AAFP SORT) Strength of 
Recommendation  
Liu et al., 2015 The degree of decrease in total daily dose of insulin needed 
to hold euglycemia during the two weeks after STII was 
predictive of relapse vs. remission. (greater decrease = 
greater chance of remission). 
Level 2 Evidence – Case Control that addressed 
change in total daily dose (TDD) of insulin needed to 
maintain glycemic target after STII and how this 
predicts relapse vs. remission 
B 
Cheng et al., 2015 STII therapy is able to improve glycemic control and beta-
cell function at diagnosis of DMII.  After that point, it 
doesn’t matter whether insulin is continued or OAD is 
initiated in terms of these parameters. 
Level 2 Evidence – Randomized trial but no control 
group.  Compared continuing insulin vs. COAD after 
STII 
B 
Zhang et al., 2016 STII can improve beta-cell function and insulin sensitivity 
to the point of inducing drug-free remission.  Greater drop 
in acute glucagon response is predictive of remission. 
Level 2 Evidence – Single arm intervention. Small 
sample.  No control.  Looked at beta-cell function, 
insulin resistance, and remission after STII 
B 
Kramer, Zinman, Choi, 
& Retnakaran, 2016 
STII can induce a long-term drug-free remission.  Lower 
baseline A1c, better baseline beta-cell function, and shorter 
duration of DMII (less than two years) are predictive of 
remission. 
Level 2 Evidence – Case Control looking at predictors 
of remission at 48 weeks after STII 
B 
Chon et al., 2018 OAD therapy and STII can equally achieve short-term 
glycemic control, but beta-cell function, insulin sensitivity, 
and the likelihood of achieving and maintaining drug-free 
remission are better in STII group. 
Level 2 Evidence – Randomized trial but no control 
group.  Compared oral anti-diabetic drug therapy vs. 
STII in terms of remission, beta-cell function, and 
glycemic control. 
B 
Presswala & Shubrook, 
2011 
2-3 weeks of STII can lower very high A1c values (down to 
6.6% at one year post-STII), as well as induce remission 
that is still active at one year in about 50% of patients. 
Level 3 Evidence – Case series describing drug-free 
remission (i.e. “Legacy Effect”) associated with STII 
therapy. 
C 
Weng et al., 2015 Guidelines should be amended to reflect the success of STII 
in inducing DMII remission via its improvement of beta-
cell function, insulin resistance, and glycemic control. 
Level 3 Evidence – Review paper by expert panel that 
addresses compelling evidence to suggest use of STII 
therapy. 
C 
Cheng et al., 2016 Fast time to glycemic goal during STII therapy has 
implications in disease-oriented outcomes (i.e. fast TTG = 
better improvement in insulin sensitivity and slower TTG = 
better beta-cell function improvement. 
Level 3 Evidence – Case control addressing how beta-
cell function and insulin sensitivity (disease-oriented 
outcomes) correlate with time to glycemic goal during 
STII therapy. 
C 
  
Totals:   
(5) Level 1 
(8) Level 2 
(3) Level 3  
Final Strength of 
Recommendation 
Grade:  A 
Table 1.  
Continued 
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Table 2.  
Breakdown of the 16 included papers based on noted improvements in patient-oriented and disease-oriented parameters.  Also included is number of 
papers addressing predictors of glycemic remission versus relapse.  
  Number of Included Papers that Measured and Reported Improvement in the 
Following Parameters / Outcomes after STII 
Patient-Oriented 
Outcomes 
Drug-Free Remission Incidence 11 
Safety (low incidence of hypoglycemia) 8 
Predictors of DMII Remission 7 
Disease-Oriented 
Outcomes 
Glycemic Control (Hgb A1c and/or FPG) 10 
Beta-cell Function 11 
Insulin Resistance / Sensitivity 7 
 
Note. STII – Short-term intensive insulin; DMII – Type 2 Diabetes Mellitus; Hgb A1c – Glycosylated hemoglobin; FPG – Fasting Plasma Glucose 
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